| Title |
Vasculitic Neuropathies
|
|---|---|
| Published in |
Current Treatment Options in Neurology, September 2015
|
| DOI | 10.1007/s11940-015-0374-1 |
| Pubmed ID | |
| Authors |
Elie Naddaf, P. James Bonham Dyck |
| Abstract |
From pathological standpoint, we divide vasculitic neuropathies in two categories: nerve large arteriole vasculitides and nerve microvasculitis. It is also important to determine whether a large arteriole vasculitis has an infectious etiology as it entails different treatment approach. Treatment of non-infectious large arteriole vasculitides consists initially of induction therapy with corticosteroids. Adding an immunosuppressant, mainly cyclophosphamide, is often needed. Treatment of infectious large arteriole vasculitides needs a multidisciplinary approach to target both the underlying infection and the vasculitis. Corticosteroids are the first-line therapy for classic non-systemic vasculitic neuropathy. Stable or improving patients without biopsy evidence of active vasculitis can be either observed or treated. Currently, adding an immunosuppressant is only indicated for patients who continue to progress on corticosteroids alone or patients with a rapidly progressive course. The treatment of the radiculoplexus neuropathies such as diabetic lumbosacral radiculoplexus neuropathy, lumbosacral radiculoplexus neuropathy (in non-diabetic patients), and diabetic cervical radiculoplexus neuropathy, as well as painless diabetic motor neuropathy, is not well established yet. We treat patients, if they present early on in the disease course or if they have severe disabling symptoms, with IV methylprednisolone 1 g once a week for 12 weeks. |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 26% |
| Other | 4 | 15% |
| Lecturer | 1 | 4% |
| Student > Doctoral Student | 1 | 4% |
| Librarian | 1 | 4% |
| Other | 4 | 15% |
| Unknown | 9 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 48% |
| Neuroscience | 2 | 7% |
| Agricultural and Biological Sciences | 1 | 4% |
| Psychology | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 9 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2022.
All research outputs
#7,522,368
of 22,957,478 outputs
Outputs from Current Treatment Options in Neurology
#177
of 471 outputs
Outputs of similar age
#90,918
of 268,061 outputs
Outputs of similar age from Current Treatment Options in Neurology
#5
of 8 outputs
Altmetric has tracked 22,957,478 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 471 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,061 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.